KEYNOTE-189: Rate of Kidney Toxicity in Patients With NSCLC

Nino Balanchivadze, MD, FACP, discuses the rates of acute kidney injury in the KEYNOTE-189 study, which evaluated pembrolizumab and carboplatin/pemetrexed in patients with metastatic non–small cell lung cancer.

Nino Balanchivadze, MD, FACP, senior administrative fellow of the Hematology and Oncology Fellowship Program at Henry Ford Cancer Institute, discuses the rates of acute kidney injury in the KEYNOTE-189 study (NCT02578680), which evaluated pembrolizumab (Keytruda) and carboplatin/pemetrexed in patients with metastatic non–small cell lung cancer.

According to Balanchivadze, acute kidney injury was observed in 5.2% of patients in the pembrolizumab combination group, compare with 0.5% of patients in the placebo arm. Additionally, 4.2% of patients in the experimental arm had all grade increase blood creatine, of which 0.7% were grade 3 or 4. In total, renal adverse events led to discontinuation in 2% of patients.

0:08 | As we know in the KEYNOTE-189 study, acute kidney injury was observed in about 5.2% of the patients in the pembrolizumab combination group compared with only 0.5% in the placebo combination group. A total of 4.2% of the patients treated with pembrolizumab and carboplatin/pemetrexed and revealed all grade increased blood creatine, of which 0.7% were grade 3 to 4, and renal adverse events in the pembrolizumab combination group led to treatment discontinuation in about 2% of the patients. It’s also important to note that most of the patient in the trial received chemotherapy with carboplatin, as the platinum compound was only given to about 25%.